Charles Schwab
LUCD icon

Charles Schwab’s Lucid Diagnostics LUCD Stock Holding History

Charles Schwab’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348K Buy
325,312
+127,888
+65% +$138K ﹤0.01% 3308
2026
Q1 		$227K Sell
197,424
-27,497
-12% -$35K ﹤0.01% 3293
2025
Q4 		$245K Buy
224,921
+50,053
+29% +$56K ﹤0.01% 3315
2025
Q3 		$177K Hold
174,868
– – ﹤0.01% 3357
2025
Q2 		$201K Buy
+174,868
New +$226K ﹤0.01% 3372
2022
Q2 		– Sell
-10,913
Closed -$37K – 3603
2022
Q1 		$37K Hold
10,913
– – ﹤0.01% 3560
2021
Q4 		$59K Buy
+10,913
New +$88.6K ﹤0.01% 3497

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Charles Schwab's LUCD Position: Q2 2026 in Review

Charles Schwab increased its Lucid Diagnostics (LUCD) stake by 65% in Q2 2026, buying an estimated $138K and bringing the position to 325,312 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #3308.

Charles Schwab first reported a position in LUCD in Q4 2021 and has held it in 7 quarters since. 115 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Charles Schwab held 325,312 shares of Lucid Diagnostics worth $348K as of Q2 2026.
  • Charles Schwab bought 127,888 Lucid Diagnostics shares in Q2 2026, an estimated $138K.
  • Lucid Diagnostics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3308 holding.
  • Charles Schwab first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 7 quarters since.
  • 115 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.